E. Pace et al., Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines, CANC CHEMOT, 46(6), 2000, pp. 467-476
We evaluated the :antiproliferative and the proapoptotic ability of gemcita
bine in three nonsmall-cell lung cancer (NSCLC) cell lines. NCI-H292 (mucoe
pidermoid carcinoma), NCI-CorL23 (large-cell carcinoma) and NCI-Colo699 (ad
enocarcinoma) cells were cultured with and without 0.5, 0.05 and 0.005 muM
gemcitabine for 24, 48 and 72 h, respectively. Gemcitabine exerted a strong
er and earlier antiproliferative and proapoptotic effect on H292 cells than
on CorL23 or Colo699 cells. Fas receptor expression was increased in all t
hree cell lines and was higher in Colo699 than in CorL23 cells. The incubat
ion of NSCLC with anti-Fas agonistic monoclonal antibody (CH11) induced cel
l apoptosis in H292 cells, demonstrating that the Fas receptor was function
ally active. Finally, Semcitabine and CH-11 exerted a synergistic effect on
cell apoptosis in H292 cells. This study demonstrates that gemcitabine ind
uces apoptosis in NSCLC and that this effect might be exerted by modulating
functionally active Fas expression, and these effects of gemcitabine were
stronger in H292 cells than in either CorL23 or Colo699 cells.